Applied Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Applied Therapeutics receives a Complete Response Letter from the FDA for its Galactosemia drug, prompting a strategic shift towards Sorbitol Dehydrogenase (SORD) Deficiency treatment.
Applied Therapeutics' 2023 10-K filing highlights advancements in their pipeline, including regulatory submissions for AT-007 and positive trial results for AT-001.